氟脲苷肝动脉持续灌注联合草酸铂静脉化疗治疗肝转移癌

目的观察经肝动脉灌注氟脲苷(FUDR)同时联合草酸铂(OXA)静脉化疗治疗肝转移癌的疗效及毒副反应.方法 28例结直肠癌或胃癌肝转移患者,经肝动脉灌注FUDR,静脉输入OXA治疗2～6个周期.所有病例均行术前术后CT扫描评价治疗效果.随访44个月,评价疗效、生存期及毒副反应.结果总有效率为42.8%,中位生存时间(MST)为25个月,出现肝转移后的MST为15.5个月,1,2,3年生存率分别为89.3%、67.8%和25.0%.结论采用新的化疗方案FUDR加OXA局部联合全身同时化疗安全有效,患者生存期得以延长.

Continuous hepatic artery infusion FUDR combined with intravenous OXA in the treatment of metastatic hepatic carcinoma

Objective To evaluate the efficacy and adverse effect of continuous hepatic artery infusion FUDR combined with intravenous OXA in the treatment of metastatic hepatic carcinoma.Methods Twenty-eight patients were treated with continuous intrahepatic arterial infusion FUDR combined with intravenous OXA.All of the patients were suffered from liver metastases of colorectal or gastric cancer.2-6 cycles were performed.All of the cases were followed up 44 months.CT scan were performed in all of the patients before and after chemotherapy to evaluate the efficacy of the treatment.Results The overall response rate was 42.8%.Median survival time(MST) was 25 months,MST was 15.5 months in liver metastases later.The survival rates at 1-year,2-year and 3-year were 89.3%,67.8% and 25.0%,respectively.There was no severe side effect or complication.Conclusion New chemotherapy regimen FUDR/OXA was safety and efficacy with local therapy combined system therapy and can prolong life span of the patients.